Cargando…

EZN-2208 treatment suppresses chronic lymphocytic leukaemia by interfering with environmental protection and increases response to fludarabine

The transcription factor HIF-1α is overexpressed in chronic lymphocytic leukaemia (CLL), where it promotes leukaemia progression by favouring the interaction of leukaemic cells with protective tissue microenvironments. Here, we tested the hypothesis that a pharmacological compound previously shown t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Valsecchi, Roberta, Coltella, Nadia, Magliulo, Daniela, Bongiovanni, Lucia, Scarfò, Lydia, Ghia, Paolo, Ponzoni, Maurilio, Bernardi, Rosa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Royal Society 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7276525/ https://www.ncbi.nlm.nih.gov/pubmed/32397871 http://dx.doi.org/10.1098/rsob.190262

Ejemplares similares

Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects
por: Sapra, Puja, et al.
Publicado: (2011)

EZN-2208 (PEG-SN38) Overcomes ABCG2-Mediated Topotecan Resistance in BRCA1-Deficient Mouse Mammary Tumors
por: Zander, Serge A. L., et al.
Publicado: (2012)

Establishment and Characterization of PCL12, a Novel CD5(+) Chronic Lymphocytic Leukaemia Cell Line
por: Agathangelidis, Andreas, et al.
Publicado: (2015)

Correction: Establishment and Characterization of PCL12, a Novel CD5+ Chronic Lymphocytic Leukaemia Cell Line
por: Agathangelidis, Andreas, et al.
Publicado: (2015)

Hypoxia inducible factor-1α regulates a pro-invasive phenotype in acute monocytic leukemia
por: Migliavacca, Jessica, et al.
Publicado: (2016)

HIF factors cooperate with PML-RARα to promote acute promyelocytic leukemia progression and relapse
por: Coltella, Nadia, et al.
Publicado: (2014)

Three-dimensional co-culture model of chronic lymphocytic leukemia bone marrow microenvironment predicts patient-specific response to mobilizing agents
por: Barbaglio, Federica, et al.
Publicado: (2020)

Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia
por: Gassner, Franz Josef, et al.
Publicado: (2010)

PYK2 is overexpressed in chronic lymphocytic leukaemia: A potential new therapeutic target
por: Sbrana, Francesca Vittoria, et al.
Publicado: (2023)

Phase-I trial of survivin inhibition with EZN-3042 in dogs with spontaneous lymphoma
por: Thamm, Douglas H., et al.
Publicado: (2020)

Simultaneous clinical resolution of focal segmental glomerulosclerosis associated with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab
por: Arampatzis, Spyridon, et al.
Publicado: (2011)

Quercetin induced apoptosis in association with death receptors and fludarabine in cells isolated from chronic lymphocytic leukaemia patients
por: Russo, M, et al.
Publicado: (2010)

Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia
por: Gauthier, Martin, et al.
Publicado: (2019)

A retinoic acid-dependent stroma-leukemia crosstalk promotes chronic lymphocytic leukemia progression
por: Farinello, Diego, et al.
Publicado: (2018)

Inhibition of chronic lymphocytic leukemia progression by full-length chromogranin A and its N-terminal fragment in mouse models
por: Bianco, Mimma, et al.
Publicado: (2016)

Distinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukaemia
por: Minici, Claudia, et al.
Publicado: (2017)

Marginal zone lymphoma: Diagnostic challenges among different entities
por: Bongiovanni, Lucia, et al.
Publicado: (2018)

PReS-FINAL-2208: Sacroilitis with propionibacterium acnes in a child
por: Galeotti, C, et al.
Publicado: (2013)

Fludarabine in the treatment of chronic lymphocytic leukemia: a review
por: Ricci, Francesca, et al.
Publicado: (2009)

Development of fludarabine formulations in the treatment of chronic lymphocytic leukemia
por: Janssens, Ann, et al.
Publicado: (2009)

Hepatitis B Reactivation in a HBsAg-Negative, HBcAb-Positive Patient Receiving Fludarabine for the Treatment of Chronic Lymphocytic Leukaemia
por: Toscanini, Federica, et al.
Publicado: (2011)

Synergistic apoptotic response between valproic acid and fludarabine in chronic lymphocytic leukaemia (CLL) cells involves the lysosomal protease cathepsin B
por: Yoon, J-Y, et al.
Publicado: (2013)

T-cell large granular lymphocytic leukemia: treatment experience with fludarabine
por: Costa, Renata Oliveira, et al.
Publicado: (2012)

MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia
por: Ferracin, Manuela, et al.
Publicado: (2010)

Telomerase Contributes to Fludarabine Resistance in Primary Human Leukemic Lymphocytes
por: Shawi, May, et al.
Publicado: (2013)

2208. Fibrosis Surveillance by Transient Elastography in Patients with Untreated Hepatitis C Infection
por: Adeyemi, Oluwatoyin, et al.
Publicado: (2018)

PB2208: CLUSTER ANALYSIS UNVEILS THE CLINICAL SPECTRUM OF ERDHEIM-CHESTER DISEASE
por: Tesi, Michelangelo, et al.
Publicado: (2023)

Anti-CD20 rechallenge with ofatumumab in relapsed/refractory splenic marginal zone lymphoma: the MORE trial
por: Scarfò, Lydia, et al.
Publicado: (2022)

2208. Ten years of the Irish National Outpatient Parenteral Antimicrobial Therapy (OPAT) Registry Data
por: Reidy, Paul, et al.
Publicado: (2023)

Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL)
por: Montillo, Marco, et al.
Publicado: (2008)

Fludarabine Treatment of Patient with Chronic Lymphocytic Leukemia Induces a Digital Ischemia
por: Soyaltin, Utku Erdem, et al.
Publicado: (2016)

Fludarabine Inhibits K(V)1.3 Currents in Human B Lymphocytes
por: de la Cruz, Alicia, et al.
Publicado: (2017)

2208: Patient satisfaction with the Michigan Surgical and Health Optimization Program (MSHOP): A mixed methods study
por: Gruca, Martin, et al.
Publicado: (2018)

2208. Rates of Medically-Attended RSV among US Adults: A Systematic Review and Meta-Analysis
por: McLaughlin, John M, et al.
Publicado: (2022)

Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia
por: Moussay, Etienne, et al.
Publicado: (2010)

Progressive multifocal leukoencephalopathy developing in a fludarabine naïve patient with chronic lymphocytic leukemia
por: Ooi, Melissa G, et al.
Publicado: (2009)

Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia in Ukraine
por: Mandrik, Olena, et al.
Publicado: (2015)

What Are the Attributes Prioritized in the Choice of Therapy in Chronic Lymphocytic Leukemia? A Patient-physician Cross-matching Analysis of a Discrete Choice Experiment
por: Laurenti, Luca, et al.
Publicado: (2022)

Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study
por: Egle, Alexander, et al.
Publicado: (2018)

Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cells
por: Pepper, C, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_n21ofdljl0qhpv7o29hke7p7if